News

The Pharma Letter13h
Alis Biosciences launches fund to free over $30 billion of capital for biotechs
London, UK-based Alis Biosciences, an investment fund focused on returning capital to investors that is currently trapped in ...
The Pharma Letter13h
VelaVigo bags second US out-licensing deal
The US subsidiary of Chinese biotech VelaVigo Cayman Limited has announced its second out-licensing agreement of a ...
The Pharma Letter13h
Swedish govt investing 80 million kronor in genomic medicine
The National Board of Health and Welfare will pay 80 million kronor ($8.3 million) to the national initiative Genomic ...
The Pharma Letter13h
The week in pharma: action, reaction and insight – week to April 18
On the research front last week, China-based biotech Remegen released positive Phase III results for its telitacicept in ...
The Pharma Letter14h
Impressive Phase III results for Enhertu plus pertuzumab
The DESTINY-Breast09 Phase III trial of AstraZeneca (LSE: AZN) and Daiichi Sankyo’s (TYO: 4568) Enhertu (trastuzumab ...